Integrating CRISPR Technology with Key Genetic Markers in Pancreatic Cancer: A New Frontier in Targeted Therapies
Pancreatic cancer is the result of mutations in crucial genetic markers like <i>KRAS</i> and <i>TP53</i> that make treatment challenging. This article discusses how CRISPR Cas9 technology can be combined with these markers to create treatments. CRISPR allows for the alteratio...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | SynBio |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2674-0583/3/1/1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Pancreatic cancer is the result of mutations in crucial genetic markers like <i>KRAS</i> and <i>TP53</i> that make treatment challenging. This article discusses how CRISPR Cas9 technology can be combined with these markers to create treatments. CRISPR allows for the alteration or repair of these mutations, with the aim of restoring gene function or blocking cancer-causing pathways. For instance, CRISPR has the potential to fix mutations in <i>TP53</i> or <i>CDKN2A</i> genes and restore <i>SMAD4</i> signaling or target the <i>KRAS</i> oncogene in the body’s cells. However promising, it may be that CRISPR encounters obstacles like unintentional effects and challenges in effectively delivering it to pancreatic tumor cells. Furthermore, ethical concerns, especially related to the editing of the germline, need consideration. As techniques based on CRISPR advance, there is a chance for them to transform the treatment landscape for cancer by offering personalized therapies. More studies are needed to enhance how treatments are administered accurately and safely through methods and targeted testing for effectiveness. |
|---|---|
| ISSN: | 2674-0583 |